Skip to main content
Clinical Trials/NCT03174119
NCT03174119
Unknown
Not Applicable

Luminothérapie Chez Les Patients présentant un état de la Conscience altérée: évaluations Comportementale, de Neuroimagerie et (Neuro)Physiologique.

University of Liege0 sites50 target enrollmentFebruary 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Disorder of Consciousness
Sponsor
University of Liege
Enrollment
50
Primary Endpoint
Changes in the Coma Recovery Scale-Revised scores.
Last Updated
7 years ago

Overview

Brief Summary

In this randomized, double-blind, placebo controlled project, the investigators would like to assess the effect of a specific light, as compared to placebo light, on wakefulness (circadian rhythms, homeostasy, sleep-wake cycle), awareness (perceptual and self consciousness), cognition (attention, memory) and underlying brain activity (electrophysiology and neuroimaging)

Detailed Description

The investigators will use behavioral (CRS-R, CAP, actimeter, brainstem reflexes), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.

Registry
clinicaltrials.gov
Start Date
February 2019
End Date
January 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Olivia Gosseries

Dr

University of Liege

Eligibility Criteria

Inclusion Criteria

  • disorder of consciousness
  • 6 weeks post-injury

Exclusion Criteria

  • dysautonomia
  • acute illnesses (infections with fever)
  • medication that is known to affect circadian rhythmicity (melatonin)
  • uncorrected sensorial deficits or documented history of significant neurological, neurosurgical, developpemental or psychiatric disorders
  • previously known cerebral lesions prior to the brain's insult that lead to disorder of consciousness
  • any contraindication to MRI, EEG, TMS-EEG, or PET (e.g., electronic implanted devices, active epilepsy, external ventricular drain)
  • not medically stable

Outcomes

Primary Outcomes

Changes in the Coma Recovery Scale-Revised scores.

Time Frame: 4 weeks study

Identify the improvement in sleep-wake cycle and circadian rhythm after the real light therapy exposure, with behavioral analyses and diagnosis through the CRS-R results.

Secondary Outcomes

  • Change in sleep-wake cycles through the actimetry, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in sleep-wake cycles through the hemodynamic function of the brain with functional Magnetic Resonance Imaging, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in sleep-wake cycles through the electrical activity of the brain with electroencephalography, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in sleep-wake cycles through analyses of melatonine hormone, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in sleep-wake cycles through temperature measurements, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in sleep-wake cycles through the brain metabolism with Positron Emission Tomography, after the exposition of real light instead of placebo light.(4 weeks study)
  • Change in the outcomes by the assessment of the Glasgow Outcome Scale Extended, after the study.(2 years after)
  • Change in sleep-wake cycles through the Nociception Coma Scale-Revised, after the exposition of real light instead of placebo light.(4 weeks study)

Similar Trials